Capecitabine, oxaliplatin, and bevacizumab (BCapOx) regimen for metastatic colorectal cancer

Meghan J. Garrett, James Waddell, Dominic A. Solimando

Research output: Contribution to journalArticle

Abstract

The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases. Questions or suggestions for topics should be addressed to Dominic A. Solimando, Jr, President, Oncology Pharmacy Services, Inc, 4201 Wilson Blvd #110-545, Arlington, VA 22203, e-mail: OncRxSvc@comcast.net; or J. Aubrey Waddell, Professor, University of Tennessee College of Pharmacy; Oncology Pharmacist, Pharmacy Department, Blount Memorial Hospital, 907 E. Lamar Alexander Parkway, Maryville TN 37804, e-mail: waddfour@charter.net. The information presented in this review is based on published data and clinical expertise and includes information not included in the product labeling. Incorporation of such published data provides a more robust assessment of the drugs and assists pharmacists in evaluation of orders for off-label use of these agents.

Original languageEnglish (US)
Pages (from-to)341-347
Number of pages7
JournalHospital Pharmacy
Volume52
Issue number5
DOIs
StatePublished - May 1 2017

Fingerprint

oxaliplatin
Pharmacists
Colorectal Neoplasms
Oncology
Postal Service
Product Labeling
Off-Label Use
Pharmaceutical Services
Chemotherapy
Poisons
Highway systems
Antineoplastic Agents
Labeling
Labels
Drug Therapy
Pharmaceutical Preparations
Capecitabine
Bevacizumab
Neoplasms

All Science Journal Classification (ASJC) codes

  • Pharmacy
  • Pharmacology
  • Pharmacology (medical)

Cite this

Capecitabine, oxaliplatin, and bevacizumab (BCapOx) regimen for metastatic colorectal cancer. / Garrett, Meghan J.; Waddell, James; Solimando, Dominic A.

In: Hospital Pharmacy, Vol. 52, No. 5, 01.05.2017, p. 341-347.

Research output: Contribution to journalArticle

Garrett, Meghan J. ; Waddell, James ; Solimando, Dominic A. / Capecitabine, oxaliplatin, and bevacizumab (BCapOx) regimen for metastatic colorectal cancer. In: Hospital Pharmacy. 2017 ; Vol. 52, No. 5. pp. 341-347.
@article{821ea68d97714d5ca44c4adff6bb2081,
title = "Capecitabine, oxaliplatin, and bevacizumab (BCapOx) regimen for metastatic colorectal cancer",
abstract = "The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases. Questions or suggestions for topics should be addressed to Dominic A. Solimando, Jr, President, Oncology Pharmacy Services, Inc, 4201 Wilson Blvd #110-545, Arlington, VA 22203, e-mail: OncRxSvc@comcast.net; or J. Aubrey Waddell, Professor, University of Tennessee College of Pharmacy; Oncology Pharmacist, Pharmacy Department, Blount Memorial Hospital, 907 E. Lamar Alexander Parkway, Maryville TN 37804, e-mail: waddfour@charter.net. The information presented in this review is based on published data and clinical expertise and includes information not included in the product labeling. Incorporation of such published data provides a more robust assessment of the drugs and assists pharmacists in evaluation of orders for off-label use of these agents.",
author = "Garrett, {Meghan J.} and James Waddell and Solimando, {Dominic A.}",
year = "2017",
month = "5",
day = "1",
doi = "10.1177/0018578717715353",
language = "English (US)",
volume = "52",
pages = "341--347",
journal = "Hospital Pharmacy",
issn = "0018-5787",
publisher = "Facts and Comparisons",
number = "5",

}

TY - JOUR

T1 - Capecitabine, oxaliplatin, and bevacizumab (BCapOx) regimen for metastatic colorectal cancer

AU - Garrett, Meghan J.

AU - Waddell, James

AU - Solimando, Dominic A.

PY - 2017/5/1

Y1 - 2017/5/1

N2 - The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases. Questions or suggestions for topics should be addressed to Dominic A. Solimando, Jr, President, Oncology Pharmacy Services, Inc, 4201 Wilson Blvd #110-545, Arlington, VA 22203, e-mail: OncRxSvc@comcast.net; or J. Aubrey Waddell, Professor, University of Tennessee College of Pharmacy; Oncology Pharmacist, Pharmacy Department, Blount Memorial Hospital, 907 E. Lamar Alexander Parkway, Maryville TN 37804, e-mail: waddfour@charter.net. The information presented in this review is based on published data and clinical expertise and includes information not included in the product labeling. Incorporation of such published data provides a more robust assessment of the drugs and assists pharmacists in evaluation of orders for off-label use of these agents.

AB - The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases. Questions or suggestions for topics should be addressed to Dominic A. Solimando, Jr, President, Oncology Pharmacy Services, Inc, 4201 Wilson Blvd #110-545, Arlington, VA 22203, e-mail: OncRxSvc@comcast.net; or J. Aubrey Waddell, Professor, University of Tennessee College of Pharmacy; Oncology Pharmacist, Pharmacy Department, Blount Memorial Hospital, 907 E. Lamar Alexander Parkway, Maryville TN 37804, e-mail: waddfour@charter.net. The information presented in this review is based on published data and clinical expertise and includes information not included in the product labeling. Incorporation of such published data provides a more robust assessment of the drugs and assists pharmacists in evaluation of orders for off-label use of these agents.

UR - http://www.scopus.com/inward/record.url?scp=85032438616&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032438616&partnerID=8YFLogxK

U2 - 10.1177/0018578717715353

DO - 10.1177/0018578717715353

M3 - Article

AN - SCOPUS:85032438616

VL - 52

SP - 341

EP - 347

JO - Hospital Pharmacy

JF - Hospital Pharmacy

SN - 0018-5787

IS - 5

ER -